Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 3-14 |
| Number of pages | 12 |
| Journal | Tumori |
| Volume | 105 |
| Issue number | 5_suppl |
| DOIs | |
| Publication status | Published - 2019 |
Keywords
- AIOM
- guidelines
- non-small cell lung cancer
- recommendations
- anaplastic lymphoma kinase
- antineoplastic agent
- epidermal growth factor receptor
- Article
- cancer staging
- cancer therapy
- health care personnel
- human
- maintenance therapy
- non small cell lung cancer
- oncogene
- oncologist
- physician
- practice guideline
- systemic therapy
- Italy
- lung tumor
- meta analysis
- oncology
- standards
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Health Personnel
- Humans
- Lung Neoplasms
- Medical Oncology
Fingerprint
Dive into the research topics of 'Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM)'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). / Facchinetti, F.; Pilotto, S.; Metro, G.; Baldini, E.; Bertolaccini, L.; Cappuzzo, F.; Delmonte, A.; Gasparini, S.; Inno, A.; Marchetti, A.; Passiglia, F.; Puma, F.; Ricardi, U.; Rossi, A.; Crinò, L.; Novello, S.
In: Tumori, Vol. 105, No. 5_suppl, 2019, p. 3-14.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM)
AU - Facchinetti, F.
AU - Pilotto, S.
AU - Metro, G.
AU - Baldini, E.
AU - Bertolaccini, L.
AU - Cappuzzo, F.
AU - Delmonte, A.
AU - Gasparini, S.
AU - Inno, A.
AU - Marchetti, A.
AU - Passiglia, F.
AU - Puma, F.
AU - Ricardi, U.
AU - Rossi, A.
AU - Crinò, L.
AU - Novello, S.
N1 - Cited By :1 Export Date: 26 February 2020 CODEN: TUMOA Correspondence Address: Novello, S.; Department of Oncology, University of Turin, San Luigi HospitalItaly; email: silvia.novello@unito.it Chemicals/CAS: anaplastic lymphoma kinase, 166433-56-3; epidermal growth factor receptor, 79079-06-4; Antineoplastic Agents Funding details: Università degli Studi di Verona Funding text 1: 1INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, France 2Medical Oncology, University of Verona, Verona University Hospital, Verona, Italy 3Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy 4Department of Oncology, S. Luca Hospital, Lucca, Italy 5Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy 6Department of Oncology and Hematology, AUSL Romagna, Ravenna, Italy 7Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy 8Department of Biologic Sciences and Public Health, Polytechnic University of Marche Region; Pulmonary Diseases Unit, Azienda Ospedali Riuniti, Ancona, Italy 9Medical Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, Verona, Italy References: Bray, F., Ferlay, J., Soerjomataram, I., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries (2018) CA Cancer J Clin, 68, pp. 394-424; (2018) I Numeri Del Cancro in Italia 2018, , Milan, AIOM; Jemal, A., Miller, K.D., Ma, J., Higher lung cancer incidence in young women than young men in the United States (2018) N Engl J Med, 378, pp. 1999-2009; Trama, A., Boffi, R., Contiero, P., Trends in lung cancer and smoking behavior in Italy: an alarm bell for women (2017) Tumori, 103, pp. 543-550; Sacher, A.G., Dahlberg, S.E., Heng, J., Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer (2016) JAMA Oncol, 2, pp. 313-320; Gobbini, E., Galetta, D., Tiseo, M., Molecular profiling in Italian patients with advanced non-small-cell lung cancer: an observational prospective study (2017) Lung Cancer, 111, pp. 30-37; Midha, A., Dearden, S., McCormack, R., EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII) (2015) Am J Cancer Res, 5, pp. 2892-2911; Han, J.Y., Park, K., Kim, S.W., First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung (2012) J Clin Oncol, 30, pp. 1122-1128; Maemondo, M., Inoue, A., Kobayashi, K., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR (2010) N Engl J Med, 362, pp. 2380-2388; Mitsudomi, T., Morita, S., Yatabe, Y., Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial (2010) Lancet Oncol, 11, pp. 121-128. , 2009/12/22; Mok, T.S., Wu, Y.L., Thongprasert, S., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma (2009) N Engl J Med, 361, pp. 947-957; Rosell, R., Carcereny, E., Gervais, R., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial (2012) Lancet Oncol, 13, pp. 239-246; Sequist, L.V., Yang, J.C., Yamamoto, N., Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations (2013) J Clin Oncol, 31, pp. 3327-3334; Zhou, C., Wu, Y.L., Chen, G., Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study (2011) Lancet Oncol, 12, pp. 735-742; Wu, Y.L., Zhou, C., Hu, C.P., Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial (2014) Lancet Oncol, 15, pp. 213-222; Park, K., Tan, E.H., O’Byrne, K., Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial (2016) Lancet Oncol, 17, pp. 577-589; Paz-Ares, L., Tan, E.H., O’Byrne, K., Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial (2017) Ann Oncol, 28, pp. 270-277; Urata, Y., Katakami, N., Morita, S., Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L (2016) J Clin Oncol, 34, pp. 3248-3257; Yang, J.J., Zhou, Q., Yan, H.H., A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations (2017) Br J Cancer, 116, pp. 568-574; De Pas, T., Toffalorio, F., Manzotti, M., Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations (2011) J Thorac Oncol, 6, pp. 1895-1901; Kobayashi, Y., Mitsudomi, T., Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy (2016) Cancer Sci, 107, pp. 1179-1186; Sequist, L.V., Martins, R.G., Spigel, D., First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations (2008) J Clin Oncol, 26, pp. 2442-2449; Yang, C.H., Yu, C.J., Shih, J.Y., Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy (2008) J Clin Oncol, 26, pp. 2745-2753; Yang, J.C., Sequist, L.V., Geater, S.L., Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 (2015) Lancet Oncol, 16, pp. 830-838; Lynch, T.J., Bell, D.W., Sordella, R., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib (2004) N Engl J Med, 350, pp. 2129-2139; Watanabe, S., Minegishi, Y., Yoshizawa, H., Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q (2014) J Thorac Oncol, 9, pp. 189-194; Wu, J.Y., Yu, C.J., Chang, Y.C., Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer (2011) Clin Cancer Res, 17, pp. 3812-3821; Sequist, L.V., Waltman, B.A., Dias-Santagata, D., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors (2011) Sci Transl Med, 3. , 75ra26; Yu, H.A., Arcila, M.E., Rekhtman, N., Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers (2013) Clin Cancer Res, 19, pp. 2240-2247; Oxnard, G.R., Thress, K.S., Alden, R.S., Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer (2016) J Clin Oncol, 34, pp. 3375-3382; Mok, T.S., Wu, Y.L., Ahn, M.J., Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer (2017) N Engl J Med, 376, pp. 629-640; Soria, J.C., Ohe, Y., Vansteenkiste, J., Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer (2018) N Engl J Med, 378, pp. 113-125; Dagogo-Jack, I., Shaw, A.T., Riely, G.J., Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer (2017) Clin Pharmacol Ther, 101, pp. 625-633; Lin, J.J., Riely, G.J., Shaw, A.T., Targeting ALK: precision medicine takes on drug resistance (2017) Cancer Discov, 7, pp. 137-155; Shaw, A.T., Kim, D.W., Nakagawa, K., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer (2013) N Engl J Med, 368, pp. 2385-2394; Solomon, B.J., Mok, T., Kim, D.W., First-line crizotinib versus chemotherapy in ALK-positive lung cancer (2014) N Engl J Med, 371, pp. 2167-2177; Crino, L., Ahn, M.J., De Marinis, F., Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2 (2016) J Clin Oncol, 34, pp. 2866-2873; Shaw, A.T., Kim, T.M., Crino, L., Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial (2017) Lancet Oncol, 18, pp. 874-886; Ou, S.H., Ahn, J.S., De Petris, L., Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study (2016) J Clin Oncol, 34, pp. 661-668; Shaw, A.T., Gandhi, L., Gadgeel, S., Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial (2016) Lancet Oncol, 17, pp. 234-242; Novello, S., Mazieres, J., Oh, I.J., Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study (2018) Ann Oncol, 29, pp. 1409-1416; Kim, D.W., Tiseo, M., Ahn, M.J., Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial (2017) J Clin Oncol, 35, pp. 2490-2498; Shaw, A.T., Felip, E., Bauer, T.M., Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial (2017) Lancet Oncol, 18, pp. 1590-1599; Solomon, B.J., Besse, B., Bauer, T.M., Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study (2018) Lancet Oncol, 19, pp. 1654-1667; Hida, T., Nokihara, H., Kondo, M., Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial (2017) Lancet, 390, pp. 29-39; Soria, J.C., Tan, D.S.W., Chiari, R., First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study (2017) Lancet, 389, pp. 917-929; Camidge, D.R., Peters, S., Mok, T., Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC (2018) J Clin Oncol, 36, p. 9043; Peters, S., Camidge, D.R., Shaw, A.T., Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer (2017) N Engl J Med, 377, pp. 829-838; Camidge, D.R., Kim, H.R., Ahn, M.J., Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer (2018) N Engl J Med, 379, pp. 2027-2039; Facchinetti, F., Rossi, G., Bria, E., Oncogene addiction in non-small cell lung cancer: focus on ROS1 inhibition (2017) Cancer Treat Rev, 55, pp. 83-95; Shaw, A., Lafrate, A.J., Camidge, D.R., Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001 (2016) Ann Oncol, p. 27; Shaw, A.T., Ou, S.H., Bang, Y.J., Crizotinib in ROS1-rearranged non-small-cell lung cancer (2014) N Engl J Med, 371, pp. 1963-1971; Mazieres, J., Zalcman, G., Crino, L., Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort (2015) J Clin Oncol, 33, pp. 992-999; Lim, S.M., Kim, H.R., Lee, J.S., Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement (2017) J Clin Oncol, 35, pp. 2613-2618; Planchard, D., Smit, E.F., Groen, H.J.M., Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial (2017) Lancet Oncol, 18, pp. 1307-1316; Mazieres, J., Barlesi, F., Filleron, T., Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort (2016) Ann Oncol, 27, pp. 281-286; Pilotto, S., Carbognin, L., Karachaliou, N., Tracking MET de-addiction in lung cancer: a road towards the oncogenic target (2017) Cancer Treat Rev, 60, pp. 1-11; Ferrara, R., Auger, N., Auclin, E., Clinical and translational implications of RET rearrangements in non-small cell lung cancer (2018) J Thorac Oncol, 13, pp. 27-45; Drilon, A., Laetsch, T.W., Kummar, S., Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children (2018) N Engl J Med, 378, pp. 731-739; Farago, A.F., Taylor, M.S., Doebele, R.C., Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion (2018) JCO Precis Oncol, , 2018; Reck, M., Rodriguez-Abreu, D., Robinson, A.G., Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer (2016) N Engl J Med, 375, pp. 1823-1833; Lopes, G., Wu, Y.-L., Kudaba, I., Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ⩾ 1%: open-label, phase 3 KEYNOTE-042 study (2018) J Clin Oncol, 36, p. LBA4; Gandhi, L., Rodriguez-Abreu, D., Gadgeel, S., Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer (2018) N Engl J Med, 378, pp. 2078-2092; Paz-Ares, L., Luft, A., Vicente, D., Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer (2018) N Engl J Med, 379, pp. 2040-2051; Socinski, M.A., Jotte, R.M., Cappuzzo, F., Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC (2018) N Engl J Med, 378, pp. 2288-2301; Jotte, R.M., Cappuzzo, F., Vynnychenko, I., IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC (2018) J Clin Oncol, 36, p. LBA9000; Barlesi, F., Nishio, M., Cobo, M., LBA54IMpower132: efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC) (2018) Ann Oncol, 424, p. 066. , mdy; Cappuzzo, F., McCleod, M., Hussein, M., LBA53IMpower130: progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC (2018) Ann Oncol, 424, p. 065. , mdy; Hellmann, M.D., Ciuleanu, T.E., Pluzanski, A., Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden (2018) N Engl J Med, 378, pp. 2093-2104; Borghaei, H., Hellmann, M.D., Paz-Ares, L.G., Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: results from CheckMate 227 (2018) J Clin Oncol, 36, p. 9001; Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials (1995) BMJ, 311, pp. 899-909; Delbaldo, C., Michiels, S., Syz, N., Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis (2004) JAMA, 292, pp. 470-484; Schiller, J.H., Harrington, D., Belani, C.P., Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer (2002) N Engl J Med, 346, pp. 92-98; Scagliotti, G.V., De Marinis, F., Rinaldi, M., Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer (2002) J Clin Oncol, 20, pp. 4285-4291; Fossella, F., Pereira, J.R., von Pawel, J., Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group (2003) J Clin Oncol, 21, pp. 3016-3024; Kelly, K., Crowley, J., Bunn, P.A., Jr., Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial (2001) J Clin Oncol, 19, pp. 3210-3218; Smit, E.F., van Meerbeeck, J.P., Lianes, P., Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group: EORTC 08975 (2003) J Clin Oncol, 21, pp. 3909-3917; Rossi, A., Chiodini, P., Sun, J.M., Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data (2014) Lancet Oncol, 15, pp. 1254-1262; Scagliotti, G.V., Parikh, P., von Pawel, J., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer (2008) J Clin Oncol, 26, pp. 3543-3551; Sandler, A., Gray, R., Perry, M.C., Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer (2006) N Engl J Med, 355, pp. 2542-2550; Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer (1999) J Natl Cancer Inst, 91, pp. 66-72; Gridelli, C., Perrone, F., Gallo, C., Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial (2003) J Natl Cancer Inst, 95, pp. 362-372; Davidoff, A.J., Tang, M., Seal, B., Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer (2010) J Clin Oncol, 28, pp. 2191-2197; Gridelli, C., Morabito, A., Cavanna, L., Cisplatin-based first-line treatment of elderly patients with advanced non-small-cell lung cancer: joint analysis of MILES-3 and MILES-4 phase III trials (2018) J Clin Oncol, 36, pp. 2585-2592; Quoix, E., Zalcman, G., Oster, J.P., Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial (2011) Lancet, 378, pp. 1079-1088; Santos, F.N., de Castria, T.B., Cruz, M.R., Chemotherapy for advanced non-small cell lung cancer in the elderly population (2015) Cochrane Database Syst Rev, p. CD010463; Langer, C., Li, S., Schiller, J., Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599 (2007) J Clin Oncol, 25, pp. 418-423; Morabito, A., Gebbia, V., Di Maio, M., Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study (2013) Lung Cancer, 81, pp. 77-83; Zukin, M., Barrios, C.H., Pereira, J.R., Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2 (2013) J Clin Oncol, 31, pp. 2849-2853; Ciuleanu, T., Brodowicz, T., Zielinski, C., Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study (2009) Lancet, 374, pp. 1432-1440; Paz-Ares, L., de Marinis, F., Dediu, M., Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial (2012) Lancet Oncol, 13, pp. 247-255; Paz-Ares, L.G., de Marinis, F., Dediu, M., PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer (2013) J Clin Oncol, 31, pp. 2895-2902; Fossella, F.V., DeVore, R., Kerr, R.N., Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group (2000) J Clin Oncol, 18, pp. 2354-2362; Shepherd, F.A., Dancey, J., Ramlau, R., Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (2000) J Clin Oncol, 18, pp. 2095-2103; Hanna, N., Shepherd, F.A., Fossella, F.V., Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy (2004) J Clin Oncol, 22, pp. 1589-1597; Shepherd, F.A., Rodrigues Pereira, J., Ciuleanu, T., Erlotinib in previously treated non-small-cell lung cancer (2005) N Engl J Med, 353, pp. 123-132; Garassino, M.C., Martelli, O., Broggini, M., Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial (2013) Lancet Oncol, 14, pp. 981-988; Kawaguchi, T., Ando, M., Asami, K., Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA) (2014) J Clin Oncol, 32, pp. 1902-1908; Zhao, N., Zhang, X.C., Yan, H.H., Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials (2014) Lung Cancer, 85, pp. 66-73; Borghaei, H., Paz-Ares, L., Horn, L., Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer (2015) N Engl J Med, 373, pp. 1627-1639; Brahmer, J., Reckamp, K.L., Baas, P., Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer (2015) N Engl J Med, 373, pp. 123-135; Herbst, R.S., Baas, P., Kim, D.W., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial (2016) Lancet, 387, pp. 1540-1550; Rittmeyer, A., Barlesi, F., Waterkamp, D., Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial (2017) Lancet, 389, pp. 255-265; Reck, M., Kaiser, R., Mellemgaard, A., Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial (2014) Lancet Oncol, 15, pp. 143-155; Novello, S., Kaiser, R., Mellemgaard, A., Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer (2015) Eur J Cancer, 51, pp. 317-326
PY - 2019
Y1 - 2019
N2 - The treatment landscape of metastatic non-small cell lung cancer (NSCLC) has dramatically evolved in recent years, since the recognition of several clinical–biological entities requiring personalized treatment approaches, leading to significant improvements in patients’ survival outcomes. In particular, targeted therapies acting against EGFR, ALK, and ROS1, and immunotherapeutic agents modulating the PD-1/PD-L1 axis, represent new milestones in the treatment of advanced disease, supporting a chemotherapy backbone within a multidisciplinary model. The Italian Association of Medical Oncology (AIOM) has developed evidence-based guidelines for the management of lung tumors. Given the epidemiologic relevance, this report is dedicated to the treatment of advanced/metastatic NSCLC. These guidelines serve as a practical tool for oncologists, physicians, and other healthcare professionals to easily embrace the updated key points of NSCLC treatment strategies. Considering the upcoming introduction of potential new standards of care in several disease settings, these guidelines represent a benchmark from which to move forward. © The Author(s) 2019.
AB - The treatment landscape of metastatic non-small cell lung cancer (NSCLC) has dramatically evolved in recent years, since the recognition of several clinical–biological entities requiring personalized treatment approaches, leading to significant improvements in patients’ survival outcomes. In particular, targeted therapies acting against EGFR, ALK, and ROS1, and immunotherapeutic agents modulating the PD-1/PD-L1 axis, represent new milestones in the treatment of advanced disease, supporting a chemotherapy backbone within a multidisciplinary model. The Italian Association of Medical Oncology (AIOM) has developed evidence-based guidelines for the management of lung tumors. Given the epidemiologic relevance, this report is dedicated to the treatment of advanced/metastatic NSCLC. These guidelines serve as a practical tool for oncologists, physicians, and other healthcare professionals to easily embrace the updated key points of NSCLC treatment strategies. Considering the upcoming introduction of potential new standards of care in several disease settings, these guidelines represent a benchmark from which to move forward. © The Author(s) 2019.
KW - AIOM
KW - guidelines
KW - non-small cell lung cancer
KW - recommendations
KW - anaplastic lymphoma kinase
KW - antineoplastic agent
KW - epidermal growth factor receptor
KW - Article
KW - cancer staging
KW - cancer therapy
KW - health care personnel
KW - human
KW - maintenance therapy
KW - non small cell lung cancer
KW - oncogene
KW - oncologist
KW - physician
KW - practice guideline
KW - systemic therapy
KW - Italy
KW - lung tumor
KW - meta analysis
KW - oncology
KW - standards
KW - Antineoplastic Agents
KW - Carcinoma, Non-Small-Cell Lung
KW - Health Personnel
KW - Humans
KW - Lung Neoplasms
KW - Medical Oncology
U2 - 10.1177/0300891619857418
DO - 10.1177/0300891619857418
M3 - Article
VL - 105
SP - 3
EP - 14
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 5_suppl
ER -